NSE: BIOCON · 15 October 2026 · Pre-market update
- Biocon Limited enters into a global patent settlement and license agreement with Genentech regarding Pebrilzo, its biosimilar to Pertuzumab. The agreement resolves pending disputes and establishes scheduled launch dates across key international markets including the EU, UK, and U.S. Investors will monitor how this pipeline clarity influences pre-market sentiment ahead of the October 15, 2026 market open.
- Biocon executed a global patent settlement and license agreement with Genentech to resolve all pending disputes in the U.S., Canada, and other jurisdictions concerning Perjeta (Pertuzumab). The agreement permits Biocon to launch its biosimilar Pebrilzo in the European Union and UK in Q1 of calendar year 2027, the U.S. in Q3 of calendar year 2028, and in other Rest of the World markets between 2026 and 2028, subject to regulatory approvals.
- Trading volume was 1.17 times the 20-day average daily volume.
Biocon Limited. Company News Before Market Open
Biocon Limited enters into a global patent settlement and license agreement with Genentech regarding Pebrilzo, its biosimilar to Pertuzumab. The agreement resolves pending disputes and establishes scheduled launch dates across key international markets including the EU, UK, and U.S. Investors will monitor how this pipeline clarity influences pre-market sentiment ahead of the October 15, 2026 market open.
The global patent settlement with Genentech removes ongoing litigation risks across the U.S., Canada, and other major jurisdictions. Defined launch timelines for Pebrilzo in the EU, UK, and U.S. provide commercial visibility for Biocon's oncology biosimilar pipeline. Upcoming commercialization depends on receiving final regulatory approvals for Pebrilzo across respective target regions.
33.75 lakh shares traded on 14 October 2026. This compares with a 20-day average daily volume of 28.88 lakh shares (1.17 times). The five-day average daily volume was 26.86 lakh shares.
The global patent settlement with Genentech removes ongoing litigation risks across the U.S., Canada, and other major jurisdictions. Defined launch timelines for Pebrilzo in the EU, UK, and U.S. provide commercial visibility for Biocon's oncology biosimilar pipeline. Upcoming commercialization depends on receiving final regulatory approvals for Pebrilzo across respective target regions.
Latest Company Developments
Biocon executed a global patent settlement and license agreement with Genentech to resolve all pending disputes in the U.S., Canada, and other jurisdictions concerning Perjeta (Pertuzumab). The agreement permits Biocon to launch its biosimilar Pebrilzo in the European Union and UK in Q1 of calendar year 2027, the U.S. in Q3 of calendar year 2028, and in other Rest of the World markets between 2026 and 2028, subject to regulatory approvals.
Securing clear entry timelines for key regulated markets removes litigation uncertainty and establishes commercial milestones for Biocon's biosimilar portfolio.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 15.47% on 30 June 2026. This compares with 15.49% on 29 June 2026, a change of -0.02 percentage points.
The filing reported 39 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Stock price response and volume at the October 15, 2026 market open following the global patent settlement disclosure.
- Trading activity relative to the previous close of ₹350.60 and the 20-day average close of ₹371.38.
- Price behavior near the recent 52-week low of ₹337.70 and the prior session's trading range between ₹347.00 and ₹353.00.
Other Dated Coverage
- Biocon Limited. Share Price Today: Why BIOCON Is Rising 0.82% | 14 October 2026 — 14 October 2026
- Biocon Limited. Share Price Today: Why BIOCON Is Falling 2.47% | 7 October 2026 — 7 October 2026
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
Biocon executed a global patent settlement and license agreement with Genentech to resolve all pending disputes in the U.S., Canada, and other jurisdictions concerning Perjeta (Pertuzumab). The agreement permits Biocon to launch its biosimilar Pebrilzo in the European Union and UK in Q1 of calendar year 2027, the U.S. in Q3 of calendar year 2028, and in other Rest of the World markets between 2026 and 2028, subject to regulatory approvals.
How strong was Biocon Limited.’s trading volume?
33.75 lakh shares traded, 1.17 times the 20-day average daily volume. The price and volume data are dated 14 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.